All In Biotech

Free tool

FAERS Monitor: Mestinon

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 009829 or its brand name (Mestinon, Pyridostigmine Bromide). Reports on generic versions are filed under their own applications.

Reports

7,620

Serious

5,403

71% of reports

Hospitalization

2,644

Death reported

526

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • myasthenia gravis878
  • fatigue781
  • drug ineffective635
  • asthenia614
  • off label use598
  • diarrhoea565
  • headache537
  • dyspnoea527
  • nausea480
  • muscular weakness410
  • fall389
  • dizziness344
  • malaise317
  • pain310
  • diplopia296

Reports by year received

View as table
YearReports
200461
200565
200679
200778
2008109
2009114
201099
2011138
2012145
2013121
2014120
2015221
2016325
2017311
2018377
2019499
2020548
2021438
2022448
2023718
2024903
2025951
2026751

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,539 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myasthenia gravisSignal878336.5314.9261,589
diplopiaSignal29631.828.48,709
muscular weaknessSignal41010.09.13,314
astheniaSignal6144.54.21,703
fallSignal3893.22.9605
fatigueSignal7812.82.6915
dyspnoeaSignal5272.62.4518
diarrhoeaSignal5652.42.2482
headacheSignal5372.42.2434
malaise3172.01.8160
dizziness3441.91.7150
off label use5981.91.7258
nausea4801.71.5135
pain3101.41.235
drug ineffective6351.31.255

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.